Literature DB >> 1112616

Detection of long-term cellular immunity to Coxiella burneti as assayed by lymphocyte transformation.

T R Jerrells, L P Mallavia, D J Hinrichs.   

Abstract

Delayed hypersensitivity to the antigens of Coxiella burneti, Nine Mile strain, was demonstrated in human subjects with various past histories of exposure to the organism by using lymphocyte transformation assays. Individuals with histories indicating exposure to C. burneti up to 8 years before the study demonstrated marked lymphocyte transformation in vitro to whole-cell antigens consisting of formalin-killed C. burneti phase I and phase II. These individuals also demonstrated a marked lymphocyte response to the trichloracetic acid-soluable phase I antigen. One individual who acquired Q fever during the study and one individual who received an experimental Q fever vaccine 4 years earlier were also evaluated by the lymphocyte transformation assay. It was also found that phase I trichloroacetic acid-soluble material was capable of acting as an antigen in the assay, whereas the phase II trichloroacetic acid-soluble material did not contain any antigenic material capable of causing lymphocyte transformation. The complete phase I trichloroacetic acid-soluble antigen, which was found to consist of protein and carbohydrate, was chemically fractionated into monospecific fractions. The fraction treated to eliminate carbohydrate was the only fraction found to elicit an in vitro response.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1112616      PMCID: PMC415057          DOI: 10.1128/iai.11.2.280-286.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Q FEVER VACCINATION OF HUMAN VOLUNTEERS. I. THE SEROLOGIC AND SKIN-TEST RESPONSE FOLLOWING SUBCUTANEOUS INJECTIONS.

Authors:  L LUOTO; J F BELL; M CASEY; D B LACKMAN
Journal:  Am J Hyg       Date:  1963-07

2.  Differentiation of Phase I and Phase II Coxiella burnetti by equilibrium density gradient sedimentation.

Authors:  B H HOYER; R A ORMSBEE; P FISET; D B LACKMAN
Journal:  Nature       Date:  1963-02-09       Impact factor: 49.962

3.  Phase variation of the Nine Mile and other strains of Rickettsia burneti.

Authors:  M G STOKER; P FISET
Journal:  Can J Microbiol       Date:  1956-05       Impact factor: 2.419

4.  Phase variation of Rickettsia (Coxiella) burneti; study of the antibody response in guinea pigs and rabbits.

Authors:  P FISET
Journal:  Can J Microbiol       Date:  1957-04       Impact factor: 2.419

5.  Intradermal sensitivity testing in man with a purified vaccine for Q fever.

Authors:  D B LACKMAN; E J BELL; J F BELL; E G PICKENS
Journal:  Am J Public Health Nations Health       Date:  1962-01

6.  Antigens of Coxiella burnetii. I. Extraction of antigens with non-aqueous organic solvents.

Authors:  R A ORMSBEE; E J BELL; D B LACKMAN
Journal:  J Immunol       Date:  1962-06       Impact factor: 5.422

7.  A method of purifying Coxiella burnetii and other pathogenic Rickettsiae.

Authors:  R A ORMSBEE
Journal:  J Immunol       Date:  1962-01       Impact factor: 5.422

8.  Q fever studies. XV. Development and persistence in man of complement-fixing and agglutinating antibodies to Coxiella burnetii.

Authors:  E H LENNETTE; W H CLARK; F W JENSEN; C J TOOMB
Journal:  J Immunol       Date:  1952-05       Impact factor: 5.422

9.  Spectrophotometric determination of microgram quantities of protein without nucleic acid interference.

Authors:  W E Groves; F C Davis; B H Sells
Journal:  Anal Biochem       Date:  1968-02       Impact factor: 3.365

10.  Lymphocyte transformation in rickettsioses.

Authors:  J D Coonrod; C C Shepard
Journal:  J Immunol       Date:  1971-01       Impact factor: 5.422

View more
  22 in total

Review 1.  Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

2.  Analysis of the cells involved in the lymphoproliferative response to Coxiella burnetii antigens.

Authors:  A A Izzo; B P Marmion; T Hackstadt
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  Long-Term immune responses to Coxiella burnetii after vaccination.

Authors:  Gilbert J Kersh; Kelly A Fitzpatrick; Joshua S Self; Brad J Biggerstaff; Robert F Massung
Journal:  Clin Vaccine Immunol       Date:  2012-11-28

4.  Appearance of cellular and humoral immunity in guinea pigs after infection with Coxiella burnetii administered in small-particle aerosols.

Authors:  R A Kishimoto; G T Burger
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

5.  Fat of Coxiella burnetti in macrophages from immune guinea pigs.

Authors:  R A Kishimoto; B J Veltri; F G Shirey; P G Canonico; J S Walker
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

6.  Development of specific and cross-reactive lymphocyte proliferative responses during chronic immunizing infections with Rickettsia tsutsugamushi.

Authors:  T R Jerrells; J V Osterman
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

7.  Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice.

Authors:  J C Williams; J L Cantrell
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

8.  Cell-mediated immune responses of guinea pigs to an inactivated phase I Coxiella burnetii vaccine.

Authors:  R A Kishimoto; J W Johnson; R H Kenyon; M S Ascher; E W Larson; C E Pedersen
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

9.  Host defenses in experimental scrub typhus: role of cellular immunity in heterologous protection.

Authors:  A Shirai; P J Catanzaro; S M Phillips; J V Osterman
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

10.  Serological evaluation of O fever in humans: enhanced phase I titers of immunoglobulins G and A are diagnostic for Q fever endocarditis.

Authors:  M G Peacock; R N Philip; J C Williams; R S Faulkner
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.